What we do Sai Parenterals Ltd is a diversified pharmaceutical company specializing in branded generic formulations and CDMO services across multiple therapeutic areas for domestic and international markets. |
Founded in 2,001 |
Market share A leading player with expanding presence in regulated markets like Australia, SE Asia; long-term contracts provide strong revenue visibility. |
Problem solved Addresses critical therapeutic needs via complex formulations in cardiovascular, neuropsychiatry, antibiotics, and more, serving chronic and acute diseases. |
Top clients or who we serve Serves government agencies, hospitals, pharma companies, and exclusive pharmacy chains in Australia and New Zealand; B2B and B2C focused. |
Key management Anil Kumar Karusala, Chairman and Managing Director with 31+ years pharma experience, supported by a senior management team with global expertise. |
Our journey and innovations Evolved via strategic acquisitions expanding manufacturing, R&D, and global footprint; launched innovative injectable and oral dosage forms meeting global standards. |
Where we operate India, Australia, New Zealand, Philippines, South-East Asia, Middle East, and emerging markets in Africa and Latin America. |
Top products or what we offer Offers injectables, tablets, capsules, liquid orals, and ointments across nine therapeutic areas with a strong portfolio of 302 products and 599+ registrations. |
Top brands Noumed OTC products in Australia, critical-care injectables, and branded generics under proprietary and partner labels with multi-year exclusive contracts. |
Raw materials needed Pharmaceutical APIs, excipients, packaging materials for injectables, oral solids and liquids, supplied by trusted vendors globally. |
Raw materials supplier Multiple international and domestic suppliers supporting diverse product lines, details not specified. |
Recurring vs cyclical contribution Over 50% of revenue is recurring, backed by long-term CDMO contracts and exclusive supply agreements especially in regulated markets. |
Our industry position Strong market positioning with accreditations like TGA Australia and PIC/S, leveraging a vast dossier library and integrated manufacturing. |
Financial highlights FY26 consolidated revenue Rs 381 crore, PAT Rs 14.3 crore; 63% export revenue, EBITDA margin around 10%, with strong growth focus post-IPO. |
Geographical revenue split Majority of export revenue from Australia (76%), growing contributions from Philippines and other international markets. |
Order book Secured long-term contracts including AUD 202 million OTC supply agreement in Australia and USD 11 million anti-TB contract in Philippines. |
Whats driving growth Growth driven by scaling CDMO exports, expanding regulated market footprint, new manufacturing facilities, and a rich R&D and dossier pipeline. |
Our future plans Commission new EU-GMP injectable facility, expand R&D capabilities, integrate acquisitions like Saicriti Pharma and Prathyak Laboratories, and explore US market entry. |
Our green promise No specific ESG initiatives detailed in provided data. |
Our people and values Diverse team of over 150 personnel in R&D and manufacturing, emphasizing quality, compliance, and innovation across global operations. |
Key challenges ahead Regulatory approvals for new facilities, integration of acquisitions, and competitive pressures in regulated markets are monitored risks. |
Interesting facts Owns 451+ Australian TGA dossiers via Noumed acquisition, positioning it uniquely for accelerated entries in regulated global markets. |
Risks and strategy Mitigates regulatory and integration risks through phased capex, strong leadership, and diversified market exposure. |
